Back to Eating Disorders

Eating Disorders Research Pipeline

This page shows what publicly available data tells us about the current state of research into Eating Disorders, from NIH funding through to clinical trial activity. Data is sourced from public government registries and updated nightly.

Drugs shown in the research pipeline are not currently available as approved treatments unless separately listed under Drug Approvals. Pipeline data shows research in progress only. Always discuss current treatment options with your doctor.

NIH Total Funding

US$99.3M
Total NIH (United States) research funding tracked, in US dollars, not Australian dollars. Source: NIH Reporter.

Phase 3 Trials

1
Trials currently in Phase 3 (closest to regulatory approval). Source: ClinicalTrials.gov.

What the data suggests

AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to NIH funding data, a moderate amount of public research funding is currently directed toward eating disorders, which suggests the condition is recognised within the broader research landscape. However, the direction of that funding has been falling year on year, which may mean fewer new studies are being initiated at the public level than in previous periods. For patients, this trend is worth monitoring, as sustained funding generally helps drive progress in understanding and treating a condition.

Registry data shows activity across both early and late stage trials, including work at Phase 1 and Phase 2 as well as more advanced Phase 3 research. This spread across the pipeline suggests that some approaches are still being explored for safety and preliminary effect, while others have advanced far enough to be tested in larger groups of people. The presence of later stage trials is generally an encouraging sign that certain treatments have moved beyond the earliest phases of investigation.

No patent activity has been recorded for eating disorders in the available data, and no TGA approvals or PBS listings have been recorded in this dataset. This means that Australian patients should not assume that any new treatments emerging from current trials are yet available or approved for use in Australia. Speaking with a treating clinician or specialist is the most reliable way to understand what options may currently be accessible through the Australian healthcare system.

This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.

Data sourced from NIH Reporter, ClinicalTrials.gov, openFDA, and other public government registries. Updated nightly. This page does not constitute medical advice. Pipeline signals are indicators based on publicly available data, not predictions of clinical outcomes or regulatory decisions.